2
Clinical Trials associated with Anti-BAFFR CART(Tianjin Medical University General Hospital) / Not yet recruitingPhase 1/2IIT Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
This is an open-label, single-arm, dose-escalation study in up to 20 participants with relapsed/refractory Neuromyelitis Optica Spectrum Disorders (NMOSD). The aim is to evaluate the safety and efficacy of the treatment with BAFFR CART.
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen receptor (CAR)-targeted B-cell activating factor receptor (BAFFR) in refractory neuroimmune diseases. The study design is divided into two parts, the first of which will be given to each patient at 3 incremental dose levels to establish the maximum tolerated dose (MTD). Each disease is expected to enroll 12 patients who meet the inclusion criteria. In the second part, 15 patients per disease will be recruited to further characterize the efficacy of the MTD.
100 Clinical Results associated with Anti-BAFFR CART(Tianjin Medical University General Hospital)
100 Translational Medicine associated with Anti-BAFFR CART(Tianjin Medical University General Hospital)
100 Patents (Medical) associated with Anti-BAFFR CART(Tianjin Medical University General Hospital)
100 Deals associated with Anti-BAFFR CART(Tianjin Medical University General Hospital)